Hideko Isozaki, Ramin Sakhtemani, Ammal Abbasi, Naveed Nikpour, Marcello Stanzione, Sunwoo Oh, Adam Langenbucher, Susanna Monroe, Wenjia Su, Heidie Frisco Cabanos, Faria M Siddiqui, Nicole Phan, Pégah Jalili, Daria Timonina, Samantha Bilton, Maria Gomez-Caraballo, Hannah L Archibald, Varuna Nangia, Kristin Dionne, Amanda Riley, Matthew Lawlor, Mandeep Kaur Banwait, Rosemary G Cobb, Lee Zou, Nicholas J Dyson, Christopher J Ott, Cyril Benes, Gad Getz, Chang S Chan, Alice T Shaw, Justin F Gainor, Jessica J Lin, Lecia V Sequist, Zofia Piotrowska, Beow Y Yeap, Jeffrey A Engelman, Jake June-Koo Lee, Yosef E Maruvka, Rémi Buisson, Michael S Lawrence, Aaron N Hata
Acquired drug resistance to anticancer targeted therapies remains an unsolved clinical problem. Although many drivers of acquired drug resistance have been identified1-4 , the underlying molecular mechanisms shaping tumour evolution during treatment are incompletely understood. Genomic profiling of patient tumours has implicated apolipoprotein B messenger RNA editing catalytic polypeptide-like (APOBEC) cytidine deaminases in tumour evolution; however, their role during therapy and the development of acquired drug resistance is undefined...
July 5, 2023: Nature